Welcome to LookChem.com Sign In|Join Free

CAS

  • or

110931-77-6

Post Buying Request

110931-77-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

110931-77-6 Usage

Uses

3-(2,4-Difluorobenzoyl)propionic Acid is a reagent used in the synthesis of a variety of antimycotics.

Check Digit Verification of cas no

The CAS Registry Mumber 110931-77-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,0,9,3 and 1 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 110931-77:
(8*1)+(7*1)+(6*0)+(5*9)+(4*3)+(3*1)+(2*7)+(1*7)=96
96 % 10 = 6
So 110931-77-6 is a valid CAS Registry Number.

110931-77-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-(2,4-Difluorophenyl)-4-oxobutanoic acid

1.2 Other means of identification

Product number -
Other names 4-(2,4-Difluorophenyl)-4-oxobutanoic Acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:110931-77-6 SDS

110931-77-6Relevant articles and documents

Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors

Teske, Kelly A.,Dash, Radha Charan,Morel, Shana R.,Chau, Lianne Q.,Wechsler-Reya, Robert J.,Hadden, M. Kyle

, p. 320 - 332 (2019)

Inhibition of the hedgehog (Hh) signaling pathway has been validated as a therapeutic strategy to treat basal cell carcinoma and holds potential for several other forms of human cancer. Itraconazole and posaconazole are clinically useful triazole anti-fungals that are being repurposed as anti-cancer agents based on their ability to inhibit the Hh pathway. We have previously demonstrated that removal of the triazole from itraconazole does not affect its ability to inhibit the Hh pathway while abolishing its primary side effect, potent inhibition of Cyp3A4. To develop structure-activity relationships for the related posaconazole scaffold, we synthesized and evaluated a series of des-triazole analogues designed through both ligand- and structure-based methods. These compounds demonstrated improved anti-Hh properties compared to posaconazole and enhanced stability without inhibiting Cyp3A4. In addition, we utilized a series of molecular dynamics and binding energy studies to probe specific interactions between the compounds and their proposed binding site on Smoothened. These studies strongly suggest that the tetrahydrofuran region of the scaffold projects out of the binding site and that π-π interactions between the compound and Smoothened play a key role in stabilizing the bound analogues.

NOVEL PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

-

Page/Page column 27-28, (2016/02/29)

The invention provides novel compounds having the general formula wherein R1, R2, R3, X and a are as described in the description and in the claims, as well as or pharmaceutically acceptable salts thereof. The invention also contains compositions including the compounds and methods of using the compounds.

Racemic and chiral lactams as potent, selective and functionally active CCR4 antagonists

Newhouse, Bradley,Allen, Shelley,Fauber, Benjamin,Anderson, Aaron S.,Eary, C. Todd,Hansen, Joshua D.,Schiro, Justin,Gaudino, John J.,Laird, Ellen,Chantry, David,Eberhardt, Christine,Burgess, Laurence E.

, p. 5537 - 5542 (2007/10/03)

A series of racemic and chiral, nonracemic lactams that display high binding affinities, functional chemotaxis antagonism, and selectivity toward CCR4 are described. Compound 41, which provides reasonably high blood levels in mice when dosed intraperitoneally, was identified as a useful pharmacological tool to explore the role of CCR4 antagonism in animal models of allergic disease. A series of racemic and chiral, nonracemic lactams that display high binding affinities, functional chemotaxis antagonism, and selectivity toward CCR4 are described. Compound 41, which provides reasonably high blood levels in mice when dosed intraperitoneally, was identified as a useful pharmacological tool to explore the role of CCR4 antagonism in animal models of allergic disease.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 110931-77-6